Company news
Nexalin Technology, Inc. news in 2025
Nexalin Technology, Inc.'s news releases, calls and decks from 2025, newest first.
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
December 3, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
December 2, 2025
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
November 18, 2025
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
November 13, 2025
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
November 5, 2025
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
October 30, 2025
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
October 21, 2025
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
October 13, 2025
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
October 10, 2025
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
October 8, 2025
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
September 25, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
August 25, 2025
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
August 1, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
May 28, 2025
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
May 13, 2025
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
May 6, 2025
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
May 5, 2025
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
May 1, 2025
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
April 24, 2025
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
April 23, 2025
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
April 21, 2025
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
April 14, 2025
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
April 2, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
March 26, 2025
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
March 3, 2025
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
February 28, 2025
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
February 26, 2025
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
February 18, 2025
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
February 9, 2025
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
February 2, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
January 22, 2025
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
January 13, 2025
Decks in 2025
- Investor Presentation (December 2025)
Investor deck · 33 slides · Dec 5, 2025
- Investor Presentation (September 2025)
Investor deck · 23 slides · September 2025
- Investor Presentation (May 2025)
Investor deck · 23 slides · May 2025